Insmed Inc (NASDAQ: INSM)’s stock price has soared by 0.06 in relation to previous closing price of 69.95. Nevertheless, the company has seen a loss of -0.96% in its stock price over the last five trading days. prnewswire.com reported 2025-01-02 that BRIDGEWATER, N.J., Jan. 2, 2025 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 43rd Annual J.P.
Is It Worth Investing in Insmed Inc (NASDAQ: INSM) Right Now?
The 36-month beta value for INSM is also noteworthy at 1.11. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 6 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for INSM is 174.61M, and at present, short sellers hold a 7.45% of that float. The average trading volume of INSM on January 03, 2025 was 1.49M shares.
INSM’s Market Performance
INSM’s stock has seen a -0.96% decrease for the week, with a -3.37% drop in the past month and a -1.98% fall in the past quarter. The volatility ratio for the week is 2.40%, and the volatility levels for the past 30 days are at 3.41% for Insmed Inc The simple moving average for the last 20 days is -2.14% for INSM’s stock, with a simple moving average of 15.65% for the last 200 days.
Analysts’ Opinion of INSM
Many brokerage firms have already submitted their reports for INSM stocks, with Truist repeating the rating for INSM by listing it as a “Buy.” The predicted price for INSM in the upcoming period, according to Truist is $48 based on the research report published on April 23, 2024 of the previous year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see INSM reach a price target of $42. The rating they have provided for INSM stocks is “Outperform” according to the report published on February 15th, 2024.
Wells Fargo gave a rating of “Overweight” to INSM, setting the target price at $55 in the report published on December 08th of the previous year.
INSM Trading at -2.26% from the 50-Day Moving Average
After a stumble in the market that brought INSM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.09% of loss for the given period.
Volatility was left at 3.41%, however, over the last 30 days, the volatility rate increased by 2.40%, as shares sank -7.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.91% lower at present.
During the last 5 trading sessions, INSM fell by -0.86%, which changed the moving average for the period of 200-days by +168.14% in comparison to the 20-day moving average, which settled at $71.52. In addition, Insmed Inc saw 1.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INSM starting from Lewis William, who proposed sale 25,580 shares at the price of $69.82 back on Jan 02 ’25. After this action, Lewis William now owns shares of Insmed Inc, valued at $1,785,915 using the latest closing price.
Lewis William, the Chair and CEO of Insmed Inc, sale 18,750 shares at $69.91 during a trade that took place back on Dec 19 ’24, which means that Lewis William is holding 384,960 shares at $1,310,799 based on the most recent closing price.
Stock Fundamentals for INSM
Current profitability levels for the company are sitting at:
- -2.14 for the present operating margin
- 0.77 for the gross margin
The net margin for Insmed Inc stands at -2.52. The total capital return value is set at -0.41. Equity return is now at value -890.75, with -51.17 for asset returns.
Based on Insmed Inc (INSM), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -0.55. The debt to equity ratio resting at 2.34. The interest coverage ratio of the stock is -9.15.
Currently, EBITDA for the company is -660.18 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 38.04. The receivables turnover for the company is 8.1for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.37.
Conclusion
In summary, Insmed Inc (INSM) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
